Literature DB >> 17116619

Clindamycin-induced anaphylactic shock during general anesthesia.

Chiuan-Shiou Chiou1, Su-Man Lin, Shih-Pin Lin, Wen-Guei Chang, Kwok-Hon Chan, Chien-Kun Ting.   

Abstract

Clindamycin-related anaphylactic reaction is rarely reported. We report a male patient with buccal cancer who was undergoing radical neck dissection when life-threatening anaphylactic shock developed soon after intravenous infusion of clindamycin. Immediate cardiopulmonary resuscitation was performed, and the patient recovered uneventfully. Perioperative anaphylactic shock is a serious problem due to the difficulty of judgment and potentially disastrous outcome. Immediate diagnosis and halting of drug infusion should be the first actions taken.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116619     DOI: 10.1016/S1726-4901(09)70327-2

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  4 in total

1.  Clindamycin-induced hypersensitivity reaction.

Authors:  Marilyn N Bulloch; Jonathan T Baccas; Scott Arnold
Journal:  Infection       Date:  2015-07-28       Impact factor: 3.553

2.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

Review 3.  Antimicrobial Desensitization: A Review of Published Protocols.

Authors:  Daniel B Chastain; Vanessa Johanna Hutzley; Jay Parekh; Jason Val G Alegro
Journal:  Pharmacy (Basel)       Date:  2019-08-09

Review 4.  Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole.

Authors:  Michelle Dilley; Bob Geng
Journal:  Clin Rev Allergy Immunol       Date:  2021-12-15       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.